Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Critical reviews in oncology/hematology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2015.08.019PMID 26358421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting TGF-β Signaling in Cancer.

  2017cited by this paper
• MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53

  2015cited by this paper
• The p53/mouse double minute 2 homolog complex deregulation in merlin‐deficient tumours

  2015cited by this paper
• Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study

  2015cited by this paper
• Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities.

  2014cited by this paper
• Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations

  2014cited by this paper
• Targeting MDM2-p53 interaction for cancer therapy: are we there yet?

  2014cited by this paper
• Multipoint targeting of the PI3K/mTOR pathway in mesothelioma

  2014cited by this paper
• Subcellular localization of Mdm2 expression and prognosis of breast cancer

  2014cited by this paper
• TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients

  2014cited by this paper
• Drugging the p53 pathway: understanding the route to clinical efficacy

  2014cited by this paper
• Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma

  2014cited by this paper
• Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.

  2014cited by this paper
• MDM2’s social network

  2014cited by this paper
• Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer

  2013cited by this paper
• Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

  2013cited by this paper
• A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.

  2013cited by this paper
• MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

  2013cited by this paper
• Molecular pathogenesis of malignant mesothelioma.

  2013cited by this paper
• Targeting TGF-β signaling in cancer

  2013cited by this paper
• Gene therapy for malignant mesothelioma: Current prospects and challenges

  2013cited by this paper
• MDM2, MDMX and p53 in oncogenesis and cancer therapy

  2013cited by this paper
• A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.

  2012cited by this paper
• Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

  2012cited by this paper
• Murine double minute‐2 expression is required for capillary maintenance and exercise‐induced angiogenesis in skeletal muscle

  2012cited by this paper
• Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.

  2012cited by this paper
• Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells

  2012cited by this paper
• Analysis of MDM2 and MDM4 Single Nucleotide Polymorphisms, mRNA Splicing and Protein Expression in Retinoblastoma

  2012cited by this paper
• Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma

  2012cited by this paper
• Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).

  2012cited by this paper
• Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

  2012cited by this paper
• TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth

  2012cited by this paper
• Mdm2 and MdmX as Regulators of Gene Expression.

  2012cited by this paper
• MDM4 is a key therapeutic target in cutaneous melanoma

  2012cited by this paper
• Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

  2012cited by this paper
• Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.

  2011cited by this paper
• Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway.

  2011cited by this paper
• MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia

  2011cited by this paper
• MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer

  2010cited by this paper
• Role of Mdm4 in drug sensitivity of breast cancer cells

  2010cited by this paper
• Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis

  2010cited by this paper
• Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

  2010cited by this paper
• A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM).

  2009cited by this paper
• p53 and E2f: partners in life and death

  2009cited by this paper
• Functional inactivation of NF2/merlin in human mesothelioma.

  2009cited by this paper
• TGFBI deficiency predisposes mice to spontaneous tumor development.

  2009cited by this paper
• Mdm2 affects genome stability independent of p53.

  2009cited by this paper
• p21 in cancer: intricate networks and multiple activities

  2009cited by this paper
• Malignant pleural mesothelioma.

  2009cited by this paper
• MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers

  2008cited by this paper
• ATM mediates repression of DNA end-degradation in an ATP-dependent manner.

  2008cited by this paper
• Mdm2 Promotes Genetic Instability and Transformation Independent of p53

  2008cited by this paper
• Regulation of angiogenic factors by HDM2 in renal cell carcinoma.

  2008cited by this paper
• Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells

  2008cited by this paper
• Phosphorylation of MDMX Mediated by Akt Leads to Stabilization and Induces 14-3-3 Binding*

  2008cited by this paper
• Regulation of MDMX Expression by Mitogenic Signaling

  2008cited by this paper
• TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta.

  2007cited by this paper
• Update on the molecular biology of malignant mesothelioma

  2007cited by this paper
• Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.

  2007cited by this paper
• The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.

  2007cited by this paper
• TGFBIp/βig-h3 protein: A versatile matrix molecule induced by TGF-β

  2007cited by this paper
• Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM)

  2006cited by this paper
• Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

  2006cited by this paper
• Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).

  2006cited by this paper
• p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.

  2006cited by this paper
• Mdm2 and HIF‐1α interaction in tumor cells during hypoxia

  2005cited by this paper
• Significance of HDMX‐S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis

  2005cited by this paper
• A mouse model recapitulating molecular features of human mesothelioma.

  2005cited by this paper
• Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.

  2005cited by this paper
• Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia.

  2005cited by this paper
• MDM2 and prognosis.

  2004cited by this paper
• MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).

  2004cited by this paper
• p14ARF expression in invasive breast cancers and ductal carcinoma in situ – relationships to p53 and Hdm2

  2004cited by this paper
• MDM2 Is a Negative Regulator of p21WAF1/CIP1, Independent of p53*

  2004cited by this paper
• Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis

  2003cited by this paper
• Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops

  2003cited by this paper
• MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation

  2003cited by this paper
• MDM2, an introduction.

  2003cited by this paper
• Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner.

  2002cited by this paper
• Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.

  2002cited by this paper
• Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival

  2002cited by this paper
• Immunohistochemical Markers for Prognosis of Cerebral Glioblastomas

  2002cited by this paper
• Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.

  2001cited by this paper
• p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure.

  2001cited by this paper
• Amplification of the mdm2 gene, but not expression of splice variants of mdm2 mrna, is associated with prognosis in soft tissue sarcoma

  2001cited by this paper
• A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

  2001cited by this paper
• Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

  2001cited by this paper
• Analysis of mdm2 and p53 Gene Alterations in Glioblastomas and its Correlation with Clinical Factors

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.

  2000cited by this paper
• Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells.

  2000cited by this paper
• Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression

  1999cited by this paper
• MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins.

  1999cited by this paper
• VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours

  1999cited by this paper
• MDM2 Suppresses p73 Function without Promoting p73 Degradation

  1999cited by this paper
• High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities

  1998cited by this paper
• p53-Independent Role of MDM2 in TGF-β1 Resistance

  1998cited by this paper
• Gene amplification as a prognostic factor in primary brain tumors.

  1998cited by this paper
• p53-independent role of MDM2 in TGF-beta1 resistance.

  1998cited by this paper
• Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.

  1998cited by this paper

• Overview on Immunopathology of Chronic Lymphocytic Leukemia and Tumor-Associated Antigens with Therapeutic Applications

  2024cites this paper
• Taraxasterol regulates p53 transcriptional activity to inhibit pancreatic cancer by inducing MDM2 ubiquitination degradation.

  2024cites this paper
• Computational biology and in vitro studies for anticipating cancer-related molecular targets of sweet wormwood (Artemisia annua)

  2023cites this paper
• MDM2- an indispensable player in tumorigenesis

  2023cites this paper
• MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors

  2023cites this paper
• Exploration of the mechanism of curcumin in the regulation of apoptosis for the treatment of colorectal cancer

  2023cites this paper
• FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations

  2023cites this paper
• Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.

  2023cites this paper
• Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy

  2023cites this paper
• Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core

  2022cites this paper
• Extracellular Citrate Treatment Induces HIF1α Degradation and Inhibits the Growth of Low-Glycolytic Hepatocellular Carcinoma under Hypoxia

  2022cites this paper
• DNA repair and damage pathways in mesothelioma development and therapy

  2022cites this paper
• Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.

  2021cites this paper
• Malignant pleural mesothelioma: an update

  2021cites this paper
• Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.

  2021cites this paper
• Expression and prognostic significance of the P53-related DNA damage repair proteins checkpoint kinase 1 (CHK1) and growth arrest and DNA-damage-inducible 45 alpha (GADD45A) in human oral squamous cell carcinoma.

  2020cites this paper
• RASSF10 regulates bone invasion of growth hormone-secreting adenomas via exosomes.

  2020cites this paper
• Evaluation of p53 and Its Target Gene Expression as Potential Biomarkers of Cholangiocarcinoma in Thai Patients

  2020cites this paper
• Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill

  2020cites this paper
• Standardized Saponin Extract from Baiye No.1 Tea (Camellia sinensis) Flowers Induced S Phase Cell Cycle Arrest and Apoptosis via AKT-MDM2-p53 Signaling Pathway in Ovarian Cancer Cells

  2020cites this paper
• Targeted Therapies in Mesothelioma

  2019cites this paper
• Pifithrin‐&agr; enhancing anticancer effect of topotecan on p53‐expressing cancer cells

  2019cites this paper
• Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies

  2019cites this paper
• Renal Epithelioid Angiomyolipoma Undergoing Aggressive Clinical Outcome: The MDM2 Expression in Tumor Cells of Two Cases.

  2019cites this paper
• MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.

  2019cites this paper
• Asbestos Exposure and Lung Carcinogenesis: Mechanism and Applications

  2019cites this paper
• Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.

  2019cites this paper
• Gene Combination of CD44 rs187116, CD133 rs2240688, NF-κB1 rs28362491 and GSTM1 Deletion as a Potential Biomarker in Risk Prediction of Breast Cancer in Lower Northern Thailand

  2019cites this paper
• miR-1305 Inhibits The Progression Of Non-Small Cell Lung Cancer By Regulating MDM2

  2019cites this paper
• Mesothelioma

  2019cites this paper
• The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies

  2019cites this paper
• Association of Cortactin and MDM2 in Solid Ameloblastoma and its Malignant Counterpart

  2019cites this paper
• Virtual Screening of Indonesian Herbal Database as Murine Double Minute-2 (MDM2) Inhibitor

  2018cites this paper
• Antileukemic and therapeutic effects of Naringenin the active principle of Citrus limetta and Citrus sinensis

  2018cites this paper
• A Transcriptional Regulatory Network Model Reveals miR-34a as a Potential Regulator of Proliferation in Cancer Cell Lines

  2018cites this paper
• Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies

  2018cites this paper
• DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response

  2018cites this paper
• Novel insights into mesothelioma biology and implications for therapy

  2017cites this paper
• 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.

  2017cites this paper
• Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors.

  2017cites this paper
• Comprehensive Landscape of Nrf2 and p53 Pathway Activation Dynamics by Oxidative Stress and DNA Damage.

  2017cites this paper
• Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas

  2017cites this paper
• Problems of Cancer Treatment. Part I. Theory of Treatment Based on Known Mechanisms of Anticancer Immunological Responses

  2017cites this paper
• Autoantibody to MDM2: A potential serological marker of primary Sjogren's syndrome

  2017cites this paper
• RasGRP3 controls cell proliferation and migration in papillary thyroid cancer by regulating the Akt-MDM2 pathway.

  2017cites this paper
• Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

  2017cites this paper
• The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence.

  2017cites this paper
• Naturaleza y origen de los cromosomas B de Locusta migratoria

  2016cites this paper
• Influence of exposure to pesticides on telomere length in tobacco farmers: A biology system approach.

  2016cites this paper
• Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB

  2016cites this paper
• NORE1A Regulates MDM2 Via β-TrCP

  2016cites this paper
• Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma

  2015cites this paper